Insoluble Organics as Electron-Transporting Materials Enabled by Solvothermal Technology for Solution-Processable Perovskite Solar Cells

Introducing electron transport materials (ETMs) into perovskite solar cells (PSCs) has opened up a new avenue to improve device efficiency. However, the most commonly used method of introducing ETMs still relies on a high-vacuum process due to their poor solubility, which prevents the application of ETMs in full solution-processable PSCs. Here, solvothermal technology is employed to treat the insoluble perylene diimide (PDI) molecule, giving the typical n-type organic semiconductor its soluble properties. The as-obtained products (PDI-CDs) as ETMs not only are suitable for the preparation of solution-processable PSCs but also have matched energy levels with adjacent components in the device. The appearance of oxygen-containing functional groups enables PDI-CDs to chelate uncoordinated Pb, suppressing interfacial recombination and improving efficiency by passivating the surface defects of perovskite crystals. The all-air processed carbon-based PSCs modified with PDI-CDs achieved a respectable power conversion efficiency of 11.90%

DataSheet2_Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model.XLSX

Objective: A prognostic model utilizing CT radiomics, radiological, and clinical features was developed and validated in this study to predict an objective response to initial transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC).Methods: Between January 2017 and December 2022, the baseline clinical characteristics and preoperative and postoperative follow-up imaging data of 108 HCC patients who underwent the first time treatment of DEB-TACE were analyzed retrospectively. The training group (n = 86) and the validation group (n = 22) were randomly assigned in an 8:2 ratio. By logistic regression in machine learning, radiomics, and clinical-radiological models were constructed separately. Finally, the integrated model construction involved the integration of both radiomics and clinical-radiological signatures. The study compared the integrated model with radiomics and clinical-radiological models using calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).Results: The objective response rate observed in a group of 108 HCC patients who received initial DEB-TACE treatment was found to be 51.9%. Among the three models, the integrated model exhibited superior predictive accuracy in both the training and validation groups. The training group resulted in an area under the curve (AUC) of 0.860, along with sensitivity and specificity values of 0.650 and 0.913, respectively. Based on the findings from the validation group, the AUC was estimated to be 0.927. Additionally, it was found that values of sensitivity and specificity were 0.875 and 0.833, respectively. In the validation group, the AUC of the integrated model showed a significant improvement when contrasted to the clinical-radiological model (p = 0.042). Nevertheless, no significant distinction was observed in the AUC when comparing the integrated model with the radiomics model (p = 0.734). The DCA suggested that the integrated model demonstrates advantageous clinical utility.Conclusion: The integrated model, which combines the CT radiomics signature and the clinical-radiological signature, exhibited higher predictive efficacy than either the radiomics or clinical-radiological models alone. This suggests that during the prediction of the objective responsiveness of HCC patients to the first DEB-TACE treatment, the integrated model yields superior outcomes.</p

DataSheet1_Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model.XLSX

Objective: A prognostic model utilizing CT radiomics, radiological, and clinical features was developed and validated in this study to predict an objective response to initial transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma (HCC).Methods: Between January 2017 and December 2022, the baseline clinical characteristics and preoperative and postoperative follow-up imaging data of 108 HCC patients who underwent the first time treatment of DEB-TACE were analyzed retrospectively. The training group (n = 86) and the validation group (n = 22) were randomly assigned in an 8:2 ratio. By logistic regression in machine learning, radiomics, and clinical-radiological models were constructed separately. Finally, the integrated model construction involved the integration of both radiomics and clinical-radiological signatures. The study compared the integrated model with radiomics and clinical-radiological models using calibration curves, receiver operating characteristic (ROC) curves, and decision curve analysis (DCA).Results: The objective response rate observed in a group of 108 HCC patients who received initial DEB-TACE treatment was found to be 51.9%. Among the three models, the integrated model exhibited superior predictive accuracy in both the training and validation groups. The training group resulted in an area under the curve (AUC) of 0.860, along with sensitivity and specificity values of 0.650 and 0.913, respectively. Based on the findings from the validation group, the AUC was estimated to be 0.927. Additionally, it was found that values of sensitivity and specificity were 0.875 and 0.833, respectively. In the validation group, the AUC of the integrated model showed a significant improvement when contrasted to the clinical-radiological model (p = 0.042). Nevertheless, no significant distinction was observed in the AUC when comparing the integrated model with the radiomics model (p = 0.734). The DCA suggested that the integrated model demonstrates advantageous clinical utility.Conclusion: The integrated model, which combines the CT radiomics signature and the clinical-radiological signature, exhibited higher predictive efficacy than either the radiomics or clinical-radiological models alone. This suggests that during the prediction of the objective responsiveness of HCC patients to the first DEB-TACE treatment, the integrated model yields superior outcomes.</p

MOESM1 of Coupling the recombineering to Cre-lox system enables simplified large-scale genome deletion in Lactobacillus casei

Additional file 1: Figure S1. Strategies for obtaining linear donor disruption cassette H1-lox66-loxP-cat-loxP-H2. Figure S2. Structure of plasmids used in this study. Arrow heads show genes and their direction. (A) LCABL_13040-50-60-expression plasmid pMSP456. (B) Cre-expression plasmid pMSPCre. LCABL_13040-50-60 and Cre were transcribed from PnisA that is controlled by the product of nisin. Figure S3. Deletion of large-scale genome region containing important gene(s) in L. casei BL23. (A) Layout and genetic context of the ~ 12.8 kb genome region and the size of PCR products amplified with primers H1F and H2R from BLD2 strains. (B) Colony PCR results. M: DNA marker; C: wild-type strain; 1–20: chloramphenicol resistance colonies. (C) Growth of L. casei BL23 and the deletion strain L. casei BLD2 on MRS. Figure S4. Cellular morphologies of L. casei strains BL23 and BLD2. Figure S5. Growth of L. casei BL23 and the deletion strain L. casei BLD3 on CDM medium containing galactose

Characterization of the promoter library.

<p>(A) Sequence analysis of the selected promoters. N = A, G, T or C. (B) Determination of promoter strength from the transcript quantification of the <i>gfp</i> gene (black) and dynamics of GFP production based on fluorescence intensity (gray). (C) Specific NoxE activity (black) under the control of eleven selected promoters (promoter activity is shown as gray). In panels (B) and (C) the values are means ± standard deviations of three independent experiments.</p

MOESM2 of Metformin exhibits the anti-proliferation and anti-invasion effects in hepatocellular carcinoma cells after insufficient radiofrequency ablation

Additional file 2: Figure S2. Metformin may regulate SMMC7721 cells proliferation, migration and invasion after insufficient RFA by promoting AMPK/PTEN/Akt pathway. Metformin was used to treat SMMC7721 cells, and western blot was used to determined the expression of p-AMPK, PTEN, p-Akt, E-cadherin, PCNA and VEGF

Promoter library for constitutive gene expression in <i>L. lactis</i>.

<p>The activity of the promoter is measured as RFU per OD600. The data are the means and standard deviations of results from five independent experiments. The arrowhead indicates the native promoter O159.</p

Metabolite accumulation and cell survival of <i>L. lactis</i> DA and the recombinant strain.

<p>Lactate production (A) and diacetyl production (B) by strains <i>L. lactis</i> DA (▪) and <i>L. lactis</i> DA/pB6nox (•) in RSM added 1% (wt/vol) glucose. Cell survival (C) and H₂O₂ accumulation (D) in <i>L. lactis</i> DA (▪) and <i>L. lactis</i> DA/pB6nox (•) after aerobic cultivation in GM 17 medium. In panels (A), (B), (C) and (D) the values are means ± standard deviations of three independent experiments.</p

Metabolic pathway of glycolysis and diacetyl biosynthesis in L. lactis.

<p>PEP, phosphoenolpyruvate; LDH, lactate dehydrogenase; ALS, α-acetolactate synthase; ALDB, acetolactate decarboxylase; PDH, pyruvate dehydrogenase; DR, diacetyl reductase; PFL, pyruvate formate lyase; NoxE, H₂O-forming NADH oxidase.</p

Plasmids used in this study.

<p>Plasmids used in this study.</p